Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
'Patients are Waiting'almost 2 years ago
Today’s New Messaging Mix: The State of Pharma Marketing in 2024almost 2 years ago
Patient Treatment & Travel: The Need for Stepped-Up Supportalmost 2 years ago
A Biosimilars Roadmap: Understanding Payer Perceptionsalmost 2 years ago
Avoiding the Digital Age is Hurting Research Effortsalmost 2 years ago
Biotech’s Road to Recovery Takes a Wobbly Turnalmost 2 years ago
Yvonne Greenstreet: Answering the Callabout 2 years ago
Lessons Learned on the Art and Science of Product CommercializationNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
2
Teva Enters $900 Million Agreement to Acquire Emalex
3
Pharmaceutical Risks in the Strait of Hormuz
4
Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher
5